A Milestone For Accelerated Approval: HIV No Longer Qualifies

FDA is ruling out the accelerated approval pathway for antiretroviral drugs to treat HIV. In a climate where sponsors are eager to expand use of the pathway, that may sound like bad news – it isn’t.

More from Clinical Trials

More from R&D